{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:06:45Z","timestamp":1791526005523,"version":"4.3.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T00:00:00Z","timestamp":1524096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Astellas Pharma Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12955-018-0892-0","type":"journal-article","created":{"date-parts":[[2018,4,19]],"date-time":"2018-04-19T13:18:58Z","timestamp":1524143938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)"],"prefix":"10.1186","volume":"16","author":[{"given":"Sender","family":"Herschorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le Mai","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Fialkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gooch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol R.","family":"Schermer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,19]]},"reference":[{"issue":"2","key":"892_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167\u201378. Epub 2002\/02\/22.","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"892_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/nau.22609","volume":"33","author":"MJ Drake","year":"2014","unstructured":"Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn. 2014;33(5):622\u20134. Epub 2014\/05\/20.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"892_CR3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/j.1464-410X.2010.09993.x","volume":"108","author":"DE Irwin","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132\u20138. Epub 2011\/01\/15.","journal-title":"BJU Int"},{"issue":"11","key":"892_CR4","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/j.1464-410X.2008.07601.x","volume":"101","author":"KS Coyne","year":"2008","unstructured":"Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388\u201395. Epub 2008\/05\/06.","journal-title":"BJU Int"},{"issue":"2 Suppl","key":"892_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.urology.2006.05.044","volume":"68","author":"P Abrams","year":"2006","unstructured":"Abrams P, Artibani W, Gajewski JB, Hussain I. Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures. Urology. 2006;68(2 Suppl):17\u201328. Epub 2006\/08\/16.","journal-title":"Urology"},{"issue":"6","key":"892_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1023\/A:1016370925601","volume":"11","author":"K Coyne","year":"2002","unstructured":"Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11(6):563\u201374. Epub 2002\/09\/11.","journal-title":"Qual Life Res"},{"issue":"3","key":"892_CR7","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s11136-004-0706-1","volume":"14","author":"KS Coyne","year":"2005","unstructured":"Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005;14(3):849\u201355. Epub 2005\/07\/19.","journal-title":"Qual Life Res"},{"issue":"6","key":"892_CR8","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2006.01.007","volume":"49","author":"KS Coyne","year":"2006","unstructured":"Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079\u201386. Epub 2006\/02\/08.","journal-title":"Eur Urol"},{"issue":"3","key":"892_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/nau.20455","volume":"27","author":"E Piault","year":"2008","unstructured":"Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P. Development and validation of the Overactive Bladder Satisfaction (OAB-S) questionnaire. Neurourol Urodyn. 2008;27(3):179\u201390. Epub 2007\/06\/15.","journal-title":"Neurourol Urodyn"},{"key":"892_CR10","unstructured":"US Food and Drug Administration Guidance for Industry. Patient reported outcome measures: use in medical product development to support labeling claims. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf . Accessed 13 Apr 2018."},{"issue":"4","key":"892_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407\u201315. Epub 1989\/12\/01.","journal-title":"Control Clin Trials"},{"issue":"2","key":"892_CR12","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/jgs.12088","volume":"61","author":"A Wagg","year":"2013","unstructured":"Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Darekar A, et al. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial. J Am Geriatr Soc. 2013;61(2):185\u201393. Epub 2013\/01\/29.","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"892_CR13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","volume":"65","author":"K Maman","year":"2014","unstructured":"Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755\u201365. Epub 2013\/11\/28.","journal-title":"Eur Urol"},{"issue":"3","key":"892_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.eururo.2008.06.047","volume":"54","author":"CR Chapple","year":"2008","unstructured":"Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543\u201362. Epub 2008\/07\/05.","journal-title":"Eur Urol"},{"issue":"7","key":"892_CR15","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/j.1464-410X.2008.07769.x","volume":"102","author":"RK Basra","year":"2008","unstructured":"Basra RK, Wagg A, Chapple C, Cardozo L, Castro-Diaz D, Pons ME, et al. A review of adherence to drug therapy in patients with overactive bladder. BJU Int. 2008;102(7):774\u20139. Epub 2008\/07\/12.","journal-title":"BJU Int"},{"issue":"9\u201310","key":"892_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.5489\/cuaj.3098","volume":"9","author":"A Wagg","year":"2015","unstructured":"Wagg A, Franks B, Ramos B, Berner T. Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: early experience in Canada. Can Urol Assoc J. 2015;9(9\u201310):343\u201350. Epub 2015\/12\/09.","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"892_CR17","first-page":"196","volume":"11","author":"S Shah","year":"2009","unstructured":"Shah S, Nitti VW. Defining efficacy in the treatment of overactive bladder syndrome. Rev Urol. 2009;11(4):196\u2013202. Epub 2010\/01\/30.","journal-title":"Rev Urol"},{"key":"892_CR18","doi-asserted-by":"crossref","unstructured":"Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multi-center study to evaluate tolerability and patient preference between mirabegron and tolterodine ER in patients with overactive bladder (PREFER study). Int Urogynecol J. 2018;29(2):273\u201383.","DOI":"10.1007\/s00192-017-3377-5"},{"key":"892_CR19","doi-asserted-by":"crossref","unstructured":"Chow S-C, Liu J-P. Design and analysis of bioavailability and bioequivalence studies. New York: Markel Dekker, Inc.; 2000.","DOI":"10.1201\/9781420002027"},{"key":"892_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2490-12-26","volume":"12","author":"SM Notte","year":"2012","unstructured":"Notte SM, Marshall TS, Lee M, Hakimi Z, Odeyemi I, Chen WH, et al. Content validity and test-retest reliability of Patient Perception of Intensity of Urgency Scale (PPIUS) for overactive bladder. BMC Urol. 2012;12:26. Epub 2012\/09\/11.","journal-title":"BMC Urol"},{"issue":"2","key":"892_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2006.03.088","volume":"176","author":"KS Coyne","year":"2006","unstructured":"Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176(2):627\u201332. discussion 32. Epub 2006\/07\/04.","journal-title":"J Urol"},{"issue":"2","key":"892_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/nau.20342","volume":"26","author":"KS Coyne","year":"2007","unstructured":"Coyne KS, Matza LS, Thompson C, Jumadilova Z, Bavendam T. The responsiveness of the OAB-q among OAB patient subgroups. Neurourol Urodyn. 2007;26(2):196\u2013203. Epub 2006\/10\/04.","journal-title":"Neurourol Urodyn"},{"issue":"7","key":"892_CR23","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/nau.21028","volume":"30","author":"KY Dyer","year":"2011","unstructured":"Dyer KY, Xu Y, Brubaker L, Nygaard I, Markland A, Rahn D, et al. Minimum important difference for validated instruments in women with urge incontinence. Neurourol Urodyn. 2011;30(7):1319\u201324. Epub 2011\/05\/13.","journal-title":"Neurourol Urodyn"},{"key":"892_CR24","doi-asserted-by":"crossref","unstructured":"Robinson D, Kelleher C, Staskin D, Mueller ER, Falconer C, Wang J, et al. Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourol Urodyn. 2018;37(1):394\u2013406.","DOI":"10.1002\/nau.23315"},{"issue":"4","key":"892_CR25","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1185\/030079907X178801","volume":"23","author":"DO Sussman","year":"2007","unstructured":"Sussman DO, Kraus SR, Carlsson M, Guan Z. Onset of efficacy of tolterodine extended release in patients with overactive bladder. Curr Med Res Opin. 2007;23(4):777\u201381. Epub 2007\/04\/05.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"892_CR26","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s11136-014-0904-4","volume":"24","author":"D Castro-Diaz","year":"2015","unstructured":"Castro-Diaz D, Chapple CR, Hakimi Z, Blauwet MB, Delgado-Herrera L, Lau W, et al. The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized phase III trials. Qual Life Res. 2015;24(7):1719\u201327. Epub 2015\/02\/18.","journal-title":"Qual Life Res"},{"issue":"6","key":"892_CR27","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/j.1742-1241.2006.00987.x","volume":"60","author":"R Roberts","year":"2006","unstructured":"Roberts R, Bavendam T, Glasser DB, Carlsson M, Eyland N, Elinoff V. Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial. Int J Clin Pract. 2006;60(6):752\u20138. Epub 2006\/06\/30.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"892_CR28","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/nau.22844","volume":"35","author":"V Khullar","year":"2016","unstructured":"Khullar V, Amarenco G, Angulo JC, Blauwet MB, Nazir J, Odeyemi IA, et al. Patient-reported outcomes with the beta3 -adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourol Urodyn. 2016;35(8):987\u201394. Epub 2015\/08\/20.","journal-title":"Neurourol Urodyn"},{"key":"892_CR29","doi-asserted-by":"crossref","unstructured":"Bunniran S, Davis C, Kristy R, Ng D, Schermer CR, Uribe C, et al. A prospective study of elderly initiating mirabegron versus antimuscarinics: patient reported outcomes from the overactive bladder satisfaction scales and other instruments. Neurourol Urodyn. 2017; Epub 2017\/04\/04.","DOI":"10.1002\/nau.23271"},{"issue":"6","key":"892_CR30","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00345-014-1244-2","volume":"32","author":"CR Chapple","year":"2014","unstructured":"Chapple CR, Nitti VW, Khullar V, Wyndaele JJ, Herschorn S, van Kerrebroeck P, et al. Onset of action of the beta3-adrenoceptor agonist, mirabegron, in phase II and III clinical trials in patients with overactive bladder. World J Urol. 2014;32(6):1565\u201372. Epub 2014\/01\/25.","journal-title":"World J Urol"},{"issue":"6","key":"892_CR31","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/nau.22800","volume":"35","author":"P Abrams","year":"2016","unstructured":"Abrams P, Paty J, Martina R, Newgreen DT, van Maanen R, Paireddy A, et al. Electronic bladder diaries of differing duration versus a paper diary for data collection in overactive bladder. Neurourol Urodyn. 2016;35(6):743\u20139. Epub 2015\/07\/16.","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"892_CR32","first-page":"e25","volume":"8","author":"V Nitti","year":"2016","unstructured":"Nitti V, Rovner E, Franks B, Muma G, Berner T, Fan A, et al. Persistence with mirabegron versus tolterodine in patients with overactive bladder. Am J Pharm Benefits. 2016;8(2):e25\u201333.","journal-title":"Am J Pharm Benefits"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-018-0892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12955-018-0892-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-018-0892-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,20]],"date-time":"2022-08-20T07:54:22Z","timestamp":1660982062000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-018-0892-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,19]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["892"],"URL":"https:\/\/doi.org\/10.1186\/s12955-018-0892-0","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,19]]},"assertion":[{"value":"2 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided Institutional Review Board (IRB)-approved written informed consent prior to any study-related procedures. The IRB approved the protocol, informed consent and patient information.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"CS, KG and TW are employees of Astellas Pharma Inc.SH has received grants, speaker and consultancy fees from Astellas, Allergan, and Ipsen, and speaker and consultancy fees from Merus and Pfizer.DS has received grants, speaker and consultancy fees from Astellas, speaker and consultancy fees from Allergan, Velicept, StimGuard, NewUro, and Inpellis, and has patents related to surgical devices for stress incontinence with royalties paid.LMT has received speaker and consultancy fees from Astellas and Pfizer.JF has received investigator fees from Astellas, and is managing director\/board chairman of Rational Surgical Solutions and has received sponsorship fees from Dendreon for Rational Surgical Solutions software application.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"69"}}